I-NK Cell immunotherapy eNdiya
NK Cell immunotherapy in India is offered by some cell therapy companies and hospitals now. NK Cell immunotherapy for treatment of recurring and complex cancer is gaining popularity by day. More and more patients are now a days going for immunotherapy treatment. NK Cell therapy is found out to be very effective in late stage treatment of cancer. So patients who are into last stage of cancer can try this therapy. NK Cell therapy in is now available in India. Uyazi imininingwane yokwelashwa nezindleko usishayele ku +91 96 1588 1588 noma ubhalele cancerfax@gmail.com.
Amasosha omzimba
Ngemuva kwezinkulungwane zeminyaka yokuziphendukela kwemvelo, umzimba womuntu uye wakha uhlelo lokuzivikela oluyinkimbinkimbi, wasungula ibutho elinamandla lokuzivikela, ligcina inani elikhulu lamasosha aphakeme, futhi lihlala lisivikela ekuhlaselweni komdlavuza. Umnkantsha uyisizinda se-Immune Corps. Lapha, amaseli e-hematopoietic stem ahlukanisa abe ama-immune fighters ahlukahlukene anemisebenzi ehlukene. Banendawo yabo yebutho kanye nezibopho zomsebenzi. Njengamanje, amabutho amathathu amasosha omzimba kanye nabangaphansi kwawo ami kanje:
1. Ama-Core Corps: Ama-Lymphocyte
Ama-T-lymphocyte, ama-lymphocyte ancike ku-thymus, angama-lymphocyte amakhulu egazini kanye nokujikeleza kabusha.
I-B-lymphocyte: Amaseli akhula ku-bursa noma isitho esilinganayo (umnkantsha). Angakwazi ukwehlukanisa abe amangqamuzana e-plasma akhiqizayo ama-antibodies lapho ikhuthazwa ngu i-antigen.
Amaseli e-NK, amaseli e-LAK awadingi umphumela wokubulala ozwela i-antigen.
2. I-Axiliary Legion: I-Antigen Yethula Iseli
I-Monocyte-macrophage phagocytosis kanye nomphumela wokubulala, i-antigen ye-TD yamanje, iqala ukuphendula kwamasosha omzimba, umphumela wokulwa nesimila, ikhiphe umlamuleli osebenzayo we-biologically.
Amaseli e-DC ayiqembu lamaseli ahlukene ananamandla amakhulu i-antigen umsebenzi owethulayo, futhi yiwo kuphela amaseli ezethulayo wesikhathi esigcwele angasebenzisa amaseli e-T asekuqaleni.
3.Amanye ama-immune cell legion
Ama-neutrophils, ama-eosinophils / ama-basophil nama-mast cell, ama-platelet, amaseli abomvu egazi.
Ayini amaseli e-NK?
Whistler-NK amaseli amasosha omzimba
Impi yokuzivikela emizimbeni yethu ifana ncamashi nempi yokulwa nesitha eboniswe efilimini. Kudinga ukuthi amabutho amathathu ahlukanise ngokucacile imisebenzi yawo, enze icebo lempi eliqinile, futhi asebenze ndawonye ukuze abhubhise isitha.
Empini yokulwa namaseli omdlavuza, amaseli e-NK "ama-whistleblower" amangalisa kakhulu.
It not only bears the brunt, it is the first to reach the isisu microenvironment to directly kill cancer cells, and it also sounds the horn of war, secretes secret weapon chemokines, and recruits dendritic cells (CD103 + DC), which is equivalent to telling other immune legions in the body Come and cooperate. The activated dendritic cells then carry tumor antigens to the lymph nodes, presenting the characteristics of the cancer cells to the killer T cells. T cells rushed to the battlefield to kill cancer cells with NK cells.
Yini i-NK Cell therapy?
Igama eligcwele lamaseli e-NK amaseli e-Natural Killer (NK), futhi iyiqembu lesithathu lama-lymphocyte ahlanganiswe namaseli T kanye no-B embuthweni wamaseli ayinhloko. Amaseli e-NK akhona egazini lomuntu futhi "angabaphenduli bokuqala". Kufana nephoyisa eliqaphayo ebelisebenza emzimbeni. Njengoba igazi ligijima nxazonke, phakathi nokugada, amaseli e-NK ayaqhubeka nokuxhumana namanye amaseli. Uma okungavamile kutholakala emzimbeni Lahla ngokushesha amaseli. Bahlasele futhi bakhipha izinhlayiya ze-cytotoxic eziqukethe i-perforin ne-granzyme kulwelwesi lwamaseli okuhlosiwe ngaphambi kokuba ama-T cell atshalwe, okwenza amangqamuzana omdlavuza azibhubhise. Baphinde baqede ukujikeleza kwamangqamuzana omdlavuza futhi basize ukuvimbela i-metastasis.
Okokuqala, izivikeli mzimba ezizalwa nazo. Impela iqhawe elihamba phambili. Cishe wonke amaseli wesimila azohlaselwa amaseli e-NK ngokukhethayo.
Okwesibili, "i-whistleblower" esimisweni sokuzivikela komzimba sinempendulo efike ngesikhathi ngesimo. Uma "isimo sesitha" sesitholakele, "sibika" ngokushesha futhi siqale ukuzivikela komzimba kanye nemisebenzi yokubulala amasosha omzimba yawo wonke amasosha omzimba.
Okwesithathu, inomphumela obanzi we-antitumor, ayidingi ukubonwa kwe-tumor ethize, futhi ayinqunyelwe umsebenzi omkhulu wokuvimbela i-histocompatibility complex (MHC) endaweni yeseli. Isikhathi sokuqalisa sishesha kakhulu, futhi ama-T cell adinga ukwethula i-antigen ngaphambi kokuba akwazi ukuhlukanisa “isitha nesitha”.
Ngakho-ke, umphumela wokubulala umdlavuza unamandla.
Izindlela ezintathu ezinkulu zokubulala umdlavuza wamaseli e-NK
Amaseli e-NK adlala indima ebalulekile emgqeni wokuqala wokuzivikela kumdlavuza. Amaseli e-NK anemiphumela emithathu yokulwa nomdlavuza:
Okokuqala, ukubulawa okuqondile kwamaseli wesimila. Ukubulala amaseli wesimila nge-post-perforin nama-granzymes noma ngama-receptors okufa;
Okwesibili, ngokukhishwa kwama-cytokines nama-chemokines ukuze adlale indima yeseli elilawulayo lesimiso somzimba sokuzivikela ezifweni, ukusebenzisa ama-T cell kanye neminye imiphumela yokubulala;
Okwesithathu, umphumela we-ADCC (umphumela we-cytotoxic oncike ku-antibody-mediated) uyakhiwa. Lapho i-B cell ithola ingqamuzana lomdlavuza, izoshiya buthule i-antibody ethile ye-IgG kuseli lomdlavuza njengophawu lokukhumbuza amaseli e-NK. Uma bebona leli seli elibhalwe ukuthi NK, babona oyedwa ebulala oyedwa. Ngosizo lwama-macrophage nama-B cell, umoya wokubulala umdlavuza ukhule kakhulu.
Ungahle uthande ukufunda: I-T Cell kanye ne-NK Cell therapy eNdiya
Ukwelashwa komzimba okwenziwe ngamaseli we-NK
Nakuba zikwazi ukuvikela ngokushesha futhi zihlasele ngokuqondile amangqamuzana e-tumor, inani lamaseli e-NK emzimbeni womuntu lincane, libalelwa ku-10% kuphela wamaseli amhlophe egazi. Futhi ucwaningo lwathola ukuthi ngemva kweminyaka engu-25 ubudala, abantu baye banciphisa ukungatheleleki futhi banciphisa inani lamaseli e-NK. Inombolo kanye nomsebenzi wamaseli e-NK ezigulini ze-tumor kanye neziguli ze-post-tumor ziye zashintsha ngezinga elithile, futhi azikwazi ukudlala indima ephumelelayo ekulweni nomphumela womdlavuza.
Researchers are now developing multiple methods to release NK cell activity against tumors, thereby increasing the efficacy and specificity of NK cell-based therapies. At present, there are three main types of NK cell strategies for tumor immunotherapy emhlabeni.
01.In vitro icushwe i-autologous noma i-allogeneic NK cell therapy
Njengamanje, ukugxila kwasekhaya nasemazweni angaphandle “ekwelapheni okutholwayo” kwamaseli e-NK kuwukuqoqa amaseli e-NK kubanikeli abasondelene nawo bese uwajova ezigulini. Lokhu kufakazele ukuthi kuphephile, futhi ngokungafani nokwelashwa kwe-T-cell, amaseli e-NK awabangeli isifo sokuxhunyelelwa ngokumelene ne-host ezicutshini zabamukeli.
02.Combining NK cells and monoclonal antibodies (such as immune checkpoint inhibitors) to induce antibody-specific cytotoxicity
Ukuhlanganisa ukwelashwa kwendawo yokuhlola nokunye ukwelashwa kwe-immunotherapy okuqondiswe yi-NK kungakhomba izinhlobo eziningi zezimila okwamanje ezingaphenduli ekwelashweni okukhona.
Nakuba indlela yokubulala yamaseli e-NK ngokumelene nezimila ingaqondile futhi ayincikile ekubonweni kwama-antigen ahlobene nesimila, zikhona futhi izindlela zokuvula noma zokucindezela izindawo zokuhlola amasosha omzimba. Ama-ligands angavezwa ngamaseli wesimila ngokumelene nezindawo zokuhlola amasosha omzimba e-NK angavimbela i-NK cell-mediated tumor cell lysis. Ngakho-ke, ukukhawulela lokhu kuvinjelwa, uchungechunge lwezindawo zokuhlola amasosha omzimba ezivimbela amaseli e-tumor-NK okwamanje athuthukiswa Ama-Antibodies.
Such as cetuximab against EGFR, cetuximab can activate the ADCC effect of NK cells and start the adaptive immune response of NK cells.
In addition, studies have found that PD-1 in NK cells is highly expressed in several cancers, including head and neck cancer, thyroid cancer, Hodgkin’s lymphoma (HL), digestive tract cancer (esophageal cancer, liver cancer, colorectal cancer, gastric cancer and biliary cancer ), Breast cancer, Kaposi’s sarcoma, renal cell carcinoma and multiple myeloma. Recent studies have shown that when PD-L1-negative tumors respond to anti-PD-L1 treatment, this effect may be mediated by PD-L1 + NK cells. PD-L1 + NK cells treated with anti-PD-L1 showed enhanced activation and effector function.
03.Yakha i-CAR-NK cell immunotherapy
I-Chimeric antigen receptor-modified NK cell: ingaba ngcono kakhulu
e ukucaciswa kokusebenza kwe-NK cell. Lo mbono ufana nokwakhiwa kwe-CAR-T: I-CAR ihlanganisa isizinda sokuqashelwa kwe-extracellular (njenge-scFv) ukuze ibone ama-antigens aqondene ne-tumor; isizinda se-transmembrane, kanye nesizinda sokusayinda esingaphakathi kweseli (iketango le-CD3ζ) lingaheha amaseli e-NK.
Yiziphi iziguli ezilungele ukwelashwa kwe-NK Cell?
Njengamanje, i-NK cell immunotherapy yasekhaya neyamazwe ngamazwe isifundwe kabanzi. Amaseli e-NK asekhaya nawaseJapane aqondiswe kakhulu kumathumba aqinile, kuyilapho ukwelapha kwe-American NK kuqondiswe kakhulu kumathumba egazi.
I-Cellular immunotherapy ingahambisana nanoma yisiphi isigaba somdlavuza, njenge:
1. Iziguli ezinethemba lokusebenzisa i-cell immunotherapy ukuze kuthuthukiswe ukuzivikela komzimba, ukususa amangqamuzana omdlavuza asele, ukuvimbela ukuphindaphinda, nokwandisa isikhathi sokuphila ngemva kokususwa kokuhlinzwa kwezilonda.
2. After radiotherapy and chemotherapy, patients with low immunity and obvious side effects (such as loss of appetite, nausea, hair loss, skin inflammation, etc.) are expected to increase the effect of chemoradiotherapy.
3. Iziguli ezesaba imiphumela emibi ye-radiotherapy kanye ne-chemotherapy futhi zithemba ukusebenzisa izindlela ezihlukahlukene zokwelapha ukufeza umphumela wokwelapha.
4. Iziguli ezinamangqamuzana omdlavuza athuthukile ziye zasakazeka kuwo wonke umzimba, kodwa iziguli ezinezindlela zokwelashwa ezivamile azikwazanga ukwenza kanjalo, zilindele ukwandisa isikhathi sokuphila nokuthuthukisa izinga lokuphila.
Important points: Cellular immunotherapy has no obvious effect on shrinking tumors in patients with advanced cancer. The effect for patients with advanced cancer is to maintain the quality of life and prolong life. The most suitable for cell immunotherapy is just after surgery. As an adjuvant therapy after surgery, to suppress recurrence and maintain early treatment of patients with early-to-middle-stage cancer; combined with chemotherapy, targeted drugs, PD1 inhibitors and other treatments, the effect will be better.
I-Cellular immunotherapy ayizifanele zonke iziguli ezinomdlavuza. Njenge-sarcoma ehlaselwe u-Wei Zexi, iyithumba elingavamile elinezinga eliphezulu lobubi. Okwamanje akukho ukwelashwa okuhle emhlabeni. Ngakho-ke, i-cell immunotherapy ayifaneleki ngokwemvelo. . Ngakho-ke, sicela uqinisekise ukuthi wena, amalungu omndeni wakho, nabangane bakho nikude nolwazi olungamanga oluku-inthanethi. Ngaphambi kokuthi ukhethe ukuthola ukwelashwa, kufanele uhlolwe ngochwepheshe esibhedlela esivamile nesigunyaziwe somdlavuza. Ngaphezu kwalokho, izindleko ze-cell immunotherapy ziphezulu uma kuqhathaniswa, akuyona yonke Imindeni engakwazi ukukwamukela. Wonke umuntu kufanele akhethe ngokucophelela ngokwezimo zezomnotho zomndeni.
Even if you cannot accept these advanced treatments, everyone should not have negative emotions. I feel that these new technologies are prepared for the rich, and the poor have to wait for death when they get cancer. This mentality is definitely not good. We all know that a good attitude is the most effective weapon to defeat cancer. Many patients have relieved all kinds of work and life pressures after suffering from cancer, relieved their hatred of some people around them, learned to forgive, learned to be grateful, and completely changed their lifestyle. Eating healthy food, regular exercise, regular work and rest, and adjusting your mentality can also achieve a longer life span, which is very important.
Yiziphi izibhedlela ezihlinzeka nge-NK Cell therapy eNdiya?
I-NK Cell therapy iwubuchwepheshe beselula futhi lokhu kunikezwa izinkampani zelashwa ngamaseli. Njengamanje kunenkampani eyodwa kuphela egunyaziwe ehlinzeka ngokwelashwa kwe-NK Cell eNdiya. Ukuze uthole imininingwane mayelana nokufaneleka kwesiguli kwe-NK Cell therapy sicela ushayele ku +91 96 1588 1588 noma uthumele iziguli imibiko yezokwelashwa kuzo cancerfax@gmail.com.
Udokotela ongcono kakhulu we-NK Cell therapy eNdiya
Njengoba kushiwo ngaphambili i-NK cell therapy e-India inikezwa izinkampani ze-cell therapy futhi zineqembu labo lodokotela abaqapha impilo yesiguli ngesikhathi sokwelashwa.
Ziyini izindleko zokwelashwa kwe-NK Cell eNdiya?
Izindleko zokwelashwa kwe-NK cell eNdiya zincike ohlotsheni kanye nezinga lomdlavuza esigulini. Kodwa-ke ngereferensi Izindleko zokwelashwa kwe-NK Cell eNdiya zingahluka phakathi $ 9000-12000 USD.
Ithini inqubo yokwelashwa kwe-NK Cell eNdiya?
Procedure and number of infusions depends upon person to person and extent & type of cancer. Please send medical reports to the below email and WhatsApp number and we shall come back with personalized treatment plan.
Ukuze wazi nge-NK Cell therapy shayela ucingo +91 96 1588 1588 noma uthumele imibiko yezempilo yesiguli ku cancerfax@gmail.com.